Reviva Presents Positive Speech Latency Data for Brilaroxazine in Schizophrenia from Phase 3 RECOVER Trial

Key Insights

• Reviva Pharmaceuticals announced positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial.
• The data will be presented as a poster at the CNS Summit 2024 in Boston, Massachusetts, on November 12th.
• The presentation will highlight how enrichment based on speech latency enhances treatment effects with brilaroxazine.

Reviva Pharmaceuticals is set to present positive speech latency data for its drug candidate, brilaroxazine, in the treatment of schizophrenia. The data originates from the Phase 3 RECOVER trial and will be shared at the CNS Summit 2024, held in Boston, Massachusetts, from November 10-13.

The poster presentation, titled "Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine," will take place on Tuesday, November 12th, from 5:00 - 7:00 PM ET. Dr. Jan Sedway from WCG Clinical will be presenting the data.

Reviva Pharmaceuticals is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases. Their pipeline includes brilaroxazine (RP5063) and RP1208, both new chemical entities discovered in-house. The company holds composition of matter patents for both drugs in the United States, Europe, and other countries.